GRI (GRI Bio Inc.) stock: $1.88, $4.1M market cap, $10.9M cash, -$6.8M EV, $5.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
MINE SAFETY DISCLOSURES 73 PART II 74 ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUE R PURCHASES OF EQUITY SECURITIES 74 I TEM 6. [RESERVED] 74 I TEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION S 74 ITEM 7A.
Partnerships Company retains global development and commercialization rights
Indications
Idiopathic pulmonary fibrosis (IPF)(Phase 2)
Status note Oral inhibitor of type 1 iNKT cells (active ingredient tazarotene). Completed randomized 12-week Phase 2a in IPF patients. FDA Orphan Drug Designation granted June 18, 2026. Evaluating Phase 2b/3 adaptive trial design with FDA feedback; requires substantial additional funding. Earlier pilot Phase 2a in chronic liver disease halted administratively. Going-concern warning disclosed.
GRI-0803
Preclinical · ActiveModality: small molecule (oral)
Target type 2 dNKT cells
Partnerships Company retains global development and commercialization rights
Status note Oral agonist of type 2 diverse NKT (dNKT) cells; lead molecule from 500+ compound library. Development previously limited pending funding; IND-enabling studies to be completed with IND filing for Phase 1a/1b in healthy volunteers expected first half of 2027.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.